Aralez Pharmaceuticals Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2016. For the quarter, the company reported total revenue of $13,628,000 compared to $5,820,000 a year ago. Net loss before taxes was $20,302,000 compared to $8,176,000 a year ago. Net loss was $20,599,000 or $0.32 per diluted common share compared to $8,149,000 or $0.25 per diluted common share a year ago. Loss from operations was $19,634,000 against $8,193,000 a year ago.

For the nine months, total revenue was $34,263,000 compared to $15,425,000 in last year. Net loss before taxes was $71,420,000 compared to $23,483,000 a year ago. Net loss was $71,862,000 or $1.26 per diluted common share compared to $24,457,000 or $0.75 per diluted common share a year ago. Loss from operations was $74,379,000 against $23,329,000 a year ago.

For the year ending December 31, 2016, the company now expects net revenues in the range of $54 million to $62 million. The company previously expected net revenues in the range of $48 million to $58 million.